En undersøgelse til evaluering (AndroMETa-CRC)
En fase 2, open-label, randomiseret, masterprotokolundersøgelse for at evaluere sikkerhed og effektivitet af flere behandlingskombinationer med telisotuzumab adizutecan hos personer med metastatisk kolorektal kræft
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Studiesteder
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2109
- Rekruttering
- Macquarie University /ID# 271514
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Rekruttering
- Mater Misericordiae /ID# 270694
-
Kontakt:
- Site Coordinator
- Telefonnummer: +61731632341
-
-
South Australia
-
Woodville South, South Australia, Australien, 5011
- Rekruttering
- The Queen Elizabeth Hospital /ID# 270693
-
-
Victoria
-
Heidelberg, Victoria, Australien, 3084
- Rekruttering
- Austin Health /ID# 270692
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Rekruttering
- One Clinical Research /ID# 270695
-
-
-
-
-
São Paulo, Brasilien, 04014-002
- Rekruttering
- Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311
-
São Paulo, Brasilien, 01401-002
- Rekruttering
- Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 41253-190
- Rekruttering
- Hospital Sao Rafael /ID# 271681
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brasilien, 98700-000
- Rekruttering
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147
-
-
São Paulo
-
Barretos, São Paulo, Brasilien, 14784-400
- Rekruttering
- Hospital De Amor /ID# 271874
-
São José do Rio Preto, São Paulo, Brasilien, 15090-000
- Rekruttering
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Rekruttering
- Arthur J.E Child Comprehensive Cancer Centre /ID# 269809
-
Edmonton, Alberta, Canada, T6G 1Z2
- Rekruttering
- Cross Cancer Institute. /ID# 272711
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Rekruttering
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- Princess Margaret Cancer Centre /ID# 268715
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Rekruttering
- Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368
-
-
-
-
-
Manchester, Det Forenede Kongerige, M20 4BX
- Rekruttering
- The Christie NHS Foundation Trust - Christie Hospital /ID# 271561
-
-
Greater London
-
London, Greater London, Det Forenede Kongerige, E1 2ES
- Rekruttering
- Barts Health NHS Trust /ID# 271189
-
-
Oxfordshire
-
Oxford, Oxfordshire, Det Forenede Kongerige, OX3 9DU
- Rekruttering
- Oxford University Hospitals Nhs Foundation Trust /ID# 272486
-
-
Surrey
-
Sutton, Surrey, Det Forenede Kongerige, SM2 5PT
- Rekruttering
- The Royal Marsden - Sutton /ID# 271172
-
-
West Midlands
-
Birmingham, West Midlands, Det Forenede Kongerige, B9 5SS
- Rekruttering
- Heartlands Hospital - University Hospitals Birmingham /ID# 271178
-
-
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Rekruttering
- City of Hope National Medical Center /ID# 270255
-
Santa Monica, California, Forenede Stater, 90404
- Rekruttering
- UCLA - Santa Monica /ID# 270621
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- Rekruttering
- Yale New Haven Hospital /ID# 270565
-
-
Florida
-
Orlando, Florida, Forenede Stater, 32803
- Rekruttering
- AdventHealth Orlando /ID# 270789
-
-
Georgia
-
Marietta, Georgia, Forenede Stater, 30060
- Rekruttering
- Northwest Georgia Oncology Centers /ID# 270245
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago Medical Center /ID# 271688
-
Hinsdale, Illinois, Forenede Stater, 60521
- Rekruttering
- Hope And Healing Cancer Services /ID# 271562
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute /ID# 270624
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109-5000
- Rekruttering
- University Of Michigan /ID# 270790
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64111
- Rekruttering
- Saint Lukes Hospital of Kansas City /ID# 270633
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68130
- Rekruttering
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- University of North Carolina at Chapel Hill /ID# 267786
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45245
- Rekruttering
- Oncology Hematology Care - Eastgate /ID# 271493
-
-
Texas
-
Austin, Texas, Forenede Stater, 78705
- Rekruttering
- Texas Oncology - Austin Midtown /ID# 271354
-
Webster, Texas, Forenede Stater, 77598
- Rekruttering
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Virginia Cancer Specialists - Fairfax /ID# 271351
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- University Of Washington /ID# 271298
-
-
-
-
-
Paris, Frankrig, 75015
- Rekruttering
- Hopital Europeen Georges Pompidou /ID# 270224
-
-
Hauts-de-France
-
Lille, Hauts-de-France, Frankrig, 59037
- Rekruttering
- Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez /ID# 270222
-
-
New Aquitaine
-
Poitiers, New Aquitaine, Frankrig, 86021
- Rekruttering
- Centre Hospitalier Universitaire de Poitiers /ID# 270225
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Frankrig, 44000
- Rekruttering
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 270221
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrig, 75013
- Rekruttering
- Hopital Pitie Salpetriere /ID# 270220
-
-
-
-
-
Thessaloniki, Grækenland, 54639
- Rekruttering
- Theagenio Cancer Hospital /ID# 269640
-
-
Attica
-
Chaïdári, Attica, Grækenland, 12462
- Rekruttering
- University General Hospital Attikon /ID# 268555
-
Nea Kifissia, Attica, Grækenland, 14564
- Rekruttering
- General Oncology Hospital of Kifisia Agioi Anargyroi /ID# 268762
-
Piraeus, Attica, Grækenland, 18547
- Rekruttering
- Metropolitan Hospital /ID# 269636
-
-
Thessaloniki
-
Panórama, Thessaloniki, Grækenland, 55236
- Rekruttering
- St. Luke's Hospital /ID# 269963
-
-
-
-
-
Haifa, Israel, 3109601
- Rekruttering
- Rambam Health Care Campus- Haifa /ID# 268006
-
Jerusalem, Israel, 9103102
- Rekruttering
- Shaare Zedek Medical Center /ID# 268009
-
Jerusalem, Israel, 91120
- Rekruttering
- Hadassah Medical Center-Hebrew University /ID# 268007
-
-
Central District
-
Petah Tikva, Central District, Israel, 4941492
- Rekruttering
- Rabin Medical Center. /ID# 268008
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Israel, 6423906
- Rekruttering
- Tel Aviv Sourasky Medical Center /ID# 268010
-
-
-
-
Milano
-
Milan, Milano, Italien, 20162
- Rekruttering
- ASST Grande Ospedale Metropolitano Niguarda /ID# 269142
-
Kontakt:
- Site Coordinator
- E-mail: ctu.oncologia@ospedaleniguarda.it
-
-
Napoli
-
Naples, Napoli, Italien, 80138
- Rekruttering
- Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 269191
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Rekruttering
- Aichi Cancer Center /ID# 270113
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Rekruttering
- National Cancer Center Hospital East /ID# 270114
-
-
Kanagawa
-
Kawasaki-shi, Kanagawa, Japan, 216-8511
- Rekruttering
- St Marianna University School Of Medicine /ID# 270111
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Rekruttering
- Tohoku University Hospital /ID# 270966
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japan, 104-0045
- Rekruttering
- National Cancer Center Hospital /ID# 270112
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Rekruttering
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268809
-
San Juan, Puerto Rico, 00917-5022
- Rekruttering
- Puerto Rico Medical Research Center /ID# 268825
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekruttering
- Hospital Universitario Vall de Hebron /ID# 270191
-
Madrid, Spanien, 28027
- Rekruttering
- Clinica Universidad de Navarra - Madrid /ID# 269754
-
Madrid, Spanien, 28046
- Rekruttering
- Hospital Universitario La Paz /ID# 269730
-
Valencia, Spanien, 46010
- Rekruttering
- Hospital Clinico Universitario de Valencia /ID# 269805
-
-
Cantabria
-
Santander, Cantabria, Spanien, 39008
- Rekruttering
- Hospital Universitario Marques de Valdecilla /ID# 269732
-
-
Navarre
-
Pamplona, Navarre, Spanien, 31008
- Rekruttering
- Clinica Universidad de Navarra - Pamplona /ID# 269753
-
-
-
-
-
Kaohsiung City, Taiwan, 807
- Rekruttering
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 269724
-
Kaohsiung City, Taiwan, 833
- Rekruttering
- Kaohsiung Chang Gung Memorial Hospital /ID# 269726
-
Tainan, Taiwan, 704
- Rekruttering
- National Cheng Kung University Hospital /ID# 270835
-
Taipei, Taiwan, 112
- Rekruttering
- Taipei Veterans General Hospital /ID# 269718
-
Taipei, Taiwan, 100
- Rekruttering
- National Taiwan University Hospital /ID# 269717
-
Taoyuan City, Taiwan, 333
- Rekruttering
- Linkou Chang Gung Memorial Hospital /ID# 269725
-
-
-
-
-
Brno, Tjekkiet, 656 53
- Rekruttering
- Masarykuv onkologicky ustav v Brne /ID# 268779
-
Hradec Králové, Tjekkiet, 500 05
- Rekruttering
- Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773
-
-
Praha 17
-
Prague, Praha 17, Tjekkiet, 128 00
- Rekruttering
- Vseobecna Fakultni nemocnice v Praze /ID# 268775
-
-
Praha 5
-
Prague, Praha 5, Tjekkiet, 150 06
- Rekruttering
- Fakultni nemocnice Motol a Homolka /ID# 268776
-
-
Praha, Hlavni Mesto
-
Prague, Praha, Hlavni Mesto, Tjekkiet, 140 59
- Rekruttering
- Fakultni Thomayerova nemocnice /ID# 269632
-
-
-
-
-
Salzburg, Østrig, 5020
- Rekruttering
- Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874
-
Vienna, Østrig, 1090
- Rekruttering
- Medizinische Universitaet Wien /ID# 268872
-
-
Styria
-
Graz, Styria, Østrig, 8010
- Rekruttering
- Medizinische Universitaet Graz /ID# 268876
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Laboratory values meeting the criteria within the protocol.
- Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
Exclusion Criteria:
- Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
- History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Substudy 1: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Eksperimentel: Substudy 1: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Eksperimentel: Substudy 1: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecandetermined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Eksperimentel: Substudy 1: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Eksperimentel: Substudy 2: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Eksperimentel: Substudy 2: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Eksperimentel: Substudy 2: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Eksperimentel: Substudy 2: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and panitumumab as part of the approximately 6 year study duration. |
IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection IV Infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.
Tidsramme: Up to 24 Weeks
|
OR is defined as confirmed CR or PR as assessed by the investigator per RECIST, version 1.1. |
Up to 24 Weeks
|
|
Number of Participants with Adverse Events (AE)s
Tidsramme: Up to Approximately 6 Years
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 6 Years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS) as Assessed by the Investigator
Tidsramme: Up to 22 Months
|
PFS is defined as the time from the first dose of study treatment to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by the investigator or death from any cause, whichever occurs earlier. |
Up to 22 Months
|
|
Duration of Response (DOR) as Assessed by the investigator
Tidsramme: Up to 14 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause, whichever occurs first. |
Up to 14 Months
|
|
Overall Survival (OS)
Tidsramme: Up to Approximately 6 Years
|
OS is defined as the time from first dose of study treatment to the event of death from any cause. |
Up to Approximately 6 Years
|
|
Disease Control (DC) as Assessed by the Investigator
Tidsramme: Up to Approximately 6 Years
|
DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by the investigator. |
Up to Approximately 6 Years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: ABBVIE INC., AbbVie
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Tyktarmssygdomme
- Kolorektale neoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Enzymer og coenzymer
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Koordinationskomplekser
- Pyrimidiner
- Formyltetrahydrofolater
- Tetrahydrofolater
- Folinsyre
- Pterins
- Pteridiner
- Uracil
- Pyrimidinoner
- Coenzymer
- Oxaliplatin
- Bevacizumab
- Panitumumab
- Fluorouracil
- Leucovorin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- M24-533
- EU CT (Anden identifikator: 2024-512981-33-00)
- 2024-512981-33-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-delingsadgangskriterier
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .